CONMED Corporation CEO Curt Hartman to Retire

CONMED Corporation announced that Curt R. Hartman will retire as President and Chief Executive Officer on January 1, 2025. Current Chief Operating Officer of CONMED, Patrick Beyer, will succeed Hartman as President and CEO and will also be appointed as a member of the company’s board, effective the same date.

“It has been a privilege to lead CONMED for the past decade, and I am incredibly proud of what we have accomplished together,” Hartman said. “The team has transformed this business into a world-class organization with a truly innovative portfolio driven by both internal research & development as well as several successful acquisitions. I am thrilled to be succeeded by Pat, as we’ve worked closely together for many years, and he was my first leadership hire when I joined CONMED in 2014. Since assuming the role of Chief Operating Officer this past April, Pat has already made a positive impact on the business, and I look forward to seeing CONMED advance even further under his leadership.”

As part of the transition, Lead Independent Director Martha Goldberg Aronson will assume the position of Chair of the Board on October 31, 2024, while Mr. Hartman will continue serving as a Director through December 31, 2024. Mr. Hartman will remain with CONMED as an advisor through March of 2027.

Beyer joined CONMED in 2014 as President of International. In October 2020, he was promoted to President of International and Global Orthopedics, where he took on the responsibilities for the company’s Global Orthopedics R&D and U.S. Orthopedics commercial business. In 2022, Beyer led the process of acquiring both In2Bones and BioRez. In April 2024, Beyer was promoted to the role of Chief Operating Officer (COO).

Before CONMED, Beyer spent 21 years at Stryker in leadership roles of increasing progression and nearly four years as CEO of ICNet International.

“I am excited to be appointed as the next President and CEO of CONMED and am extremely grateful to Curt, Martha, and the Board of Directors for the opportunity. I am honored to succeed Curt and am deeply appreciative of his leadership and mentorship over the years we have worked together, including during this transition,” Beyer commented. “I look forward to leading our team in driving further growth and innovation across our businesses and continuing to deliver state-of-the-art products to our customers, allowing them to drive better outcomes for their patients.”

“On behalf of the entire CONMED Board of Directors, I’d like to thank Curt for his extraordinary contributions to CONMED over the last 10 years,” said Aronson. “Curt has been instrumental in growing and diversifying the portfolio and expanding our business in key markets, nearly doubling the Company’s revenues and more than doubling its profitability during his tenure. Curt and his team transformed CONMED into a leader in key markets and categories across both General Surgery and Orthopedics, and the Company is in a significantly stronger position than when he joined in 2014. Curt and his team led the acquisitions of several innovative, highly impactful technologies that have been instrumental in driving the Company’s above-market growth and strong profitability.”